New York, NY (July 11, 2011) – Clinilabs, a contract research organization that provides early-phase and specialty clinical drug development services to industry, announced today that they have been selected to conduct a clinical research study of the effects of an investigational medication on the sleep of healthy volunteers.
This study employs an experimental model to assess the effects of an investigational medication on nighttime sleep and morning alertness in healthy volunteers. President and CEO, Dr. Gary Zammit, notes that the use of experimental models and biomarkers are increasingly important in early-phase drug development. Dr. Zammit states: “the current study employs an experimental model of disturbed sleep that can be used as an assay to assess the potential therapeutic effects that drugs will have in patients with sleep disorders. The model will allow our client to determine if their drug should advance to later and more costly phases of testing.” The use of such models is likely to become more common as drug makers seek more efficient ways to test investigational medications.
Clinilabs is currently enrolling healthy male and female volunteers between the ages of 21 and 65 years who are not sleep deprived and who maintain a regular sleep/wake schedule. Individuals in the New York City Metro area who would like to participate can contact our call center at 212-994-4567 to prequalify. Additional information may also be found by visiting www.clinilabs.com/healthy.
About Clinilabs Inc.
Clinilabs is a contract research organization (CRO) that provides early-phase and specialty clinical drug development services to industry. We offer teams, processes, and technology solutions that are designed to serve single center and multicenter early-phase studies – services that can be scaled as needed to meet the requirements of any clinical development program. For more information, please visit www.clinilabs.com.